Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON    MYLAN
EQUITY SHARE DATA
    BIOCON
Mar-23
MYLAN
Dec-18
BIOCON /
MYLAN
5-Yr Chart
Click to enlarge
High Rs3883,967-   
Low Rs1922,184-   
Sales per share (Unadj.) Rs93.11,825.4-  
Earnings per share (Unadj.) Rs5.449.6-  
Cash flow per share (Unadj.) Rs14.6391.3-  
Dividends per share (Unadj.) Rs1.500-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs146.51,974.7-  
Shares outstanding (eoy) m1,200.60514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.11.7 184.8%   
Avg P/E ratio x54.162.0 87.2%  
P/CF ratio (eoy) x19.87.9 252.0%  
Price / Book Value ratio x2.01.6 127.0%  
Dividend payout %28.00-   
Avg Mkt Cap Rs m347,8141,582,214 22.0%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m21,8100-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m111,742939,158 11.9%  
Other income Rs m7,6810-   
Total revenues Rs m119,423939,158 12.7%   
Gross profit Rs m16,611243,019 6.8%  
Depreciation Rs m11,131175,847 6.3%   
Interest Rs m4,19045,170 9.3%   
Profit before tax Rs m8,97122,002 40.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,541-3,500 -72.6%   
Profit after tax Rs m6,43025,502 25.2%  
Gross profit margin %14.925.9 57.4%  
Effective tax rate %28.3-15.9 -178.0%   
Net profit margin %5.82.7 211.9%  
BALANCE SHEET DATA
Current assets Rs m123,340524,425 23.5%   
Current liabilities Rs m85,107382,364 22.3%   
Net working cap to sales %34.215.1 226.2%  
Current ratio x1.41.4 105.7%  
Inventory Days Days12984 154.4%  
Debtors Days Days11793 125.1%  
Net fixed assets Rs m394,078182,181 216.3%   
Share capital Rs m6,003500 1,200.5%   
"Free" reserves Rs m169,9260-   
Net worth Rs m175,9291,015,998 17.3%   
Long term debt Rs m152,9051,096,588 13.9%   
Total assets Rs m517,4182,725,301 19.0%  
Interest coverage x3.11.5 211.2%   
Debt to equity ratio x0.91.1 80.5%  
Sales to assets ratio x0.20.3 62.7%   
Return on assets %2.12.6 79.1%  
Return on equity %3.72.5 145.6%  
Return on capital %4.03.2 125.9%  
Exports to sales %3.10-   
Imports to sales %6.00-   
Net fx Rs m-3,1870-   
CASH FLOW
From Operations Rs m18,525195,157 9.5%  
From Investments Rs m-142,818-100,875 141.6%  
From Financial Activity Rs m130,487-90,916 -143.5%  
Net Cashflow Rs m6,4111,617 396.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare BIOCON With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare BIOCON With: MOREPEN LABS  SANOFI INDIA  CIPLA  KWALITY PHARMA  GENNEX LAB.  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.